A Phase III, Multi-center, Randomized, Double-blind, Based on Standard Therapy, Placebo-controlled Study of the Efficacy/Safety of Recombinant Human Neuregulin-1beta in Patients With Chronic Systolic Heart Failure

Trial Profile

A Phase III, Multi-center, Randomized, Double-blind, Based on Standard Therapy, Placebo-controlled Study of the Efficacy/Safety of Recombinant Human Neuregulin-1beta in Patients With Chronic Systolic Heart Failure

Discontinued
Phase of Trial: Phase III

Latest Information Update: 23 Apr 2013

At a glance

  • Drugs Recombinant human neuregulin 1-beta (Primary)
  • Indications Chronic heart failure
  • Focus Pharmacodynamics; Registrational
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Aug 2012 Planned end date changed from 1 Mar 2013 to 1 Dec 2012 as reported by ClinicalTrials.gov.
    • 01 Aug 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top